首页> 外文期刊>Global Business Review >Patients' Perception Towards Branded and Generic Medicines in an Emerging Economy: A Scale Development and Validation Study
【24h】

Patients' Perception Towards Branded and Generic Medicines in an Emerging Economy: A Scale Development and Validation Study

机译:新兴经济体中患者对品牌药和非专利药的感知:规模发展和验证研究

获取原文
获取原文并翻译 | 示例
           

摘要

The study intends to develop and validate a scale to gauge the perception of patients towards branded and generic medicines in an emerging economy like India. Items were generated through literature review and exploratory semi-structured interview with patients and physicians. In the way of establishing generic medicines in the market, patients’ acceptability is very much essential. However, with the advent of information age, the patients are now becoming more conscious and aware regarding the generic medicines, and there is an improvement in the acceptability of generic medicines. Hence, the measurement of their perception towards generic medicines becomes an important issue for various stakeholders of the medical world—physicians, government, pharmaceutical companies and chemists. However, no studies regarding the measurement of perception towards the branded and generic have been conducted to develop and validate measurement scale. The present study is an attempt towards fulfilling this gap. A total of 361 valid responses were obtained using purposive sampling. Exploratory factor analysis (EFA) was carried out through principal component analysis (PCA) followed by confirmatory factor analysis (CFA) to establish the validity of the proposed measurement model. The five factors extracted from EFA were named as quality (Cronbach’s alpha: 0.887), trust (Cronbach’s alpha: 0.919), sustained effectiveness (Cronbach’s alpha: 0.832), reputation (Cronbach’s alpha: 0.881) and psychological benefits (Cronbach’s alpha: 0.737). The obtained factors were found reliable and valid for measuring perception of the patients towards generic and branded medicines in emerging market settings. Convergent and discriminant validity of the scale was also established.
机译:该研究旨在开发和验证一种量表,以衡量在诸如印度这样的新兴经济体中患者对品牌药和非专利药的看法。通过文献回顾和对患者和医生的探索性半结构化访谈产生了项目。在市场上建立仿制药的过程中,患者的可接受性非常重要。但是,随着信息时代的到来,患者对仿制药的意识和意识正在增强,仿制药的可接受性也有所提高。因此,衡量他们对仿制药的看法成为医学界各个利益相关者(医师,政府,制药公司和化学家)的重要问题。但是,尚未进行有关对品牌和一般品牌的感知量度的研究来制定和验证量表。本研究是试图弥补这一差距。目的抽样共获得361份有效应答。探索性因素分析(EFA)通过主成分分析(PCA)然后进行确认性因素分析(CFA)进行,以建立所提出的测量模型的有效性。从全民教育中提取的五个因素分别称为质量(Cronbach'sα:0.887),信任(Cronbach'sα:0.919),持续有效性(Cronbach'sα:0.832),声誉(Cronbach'sα:0.881)和心理利益(Cronbach'sα:0.737) 。发现所获得的因素可靠且有效,可用于衡量新兴市场环境中患者对仿制药和品牌药物的认知。还建立了量表的收敛性和判别力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号